Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Drug Safety Initiative Will Include New Website On Rx Risks

This article was originally published in The Pink Sheet Daily

Executive Summary

The site is intended as an avenue for the agency to disclose safety issues that have not yet been definitively reviewed, and to emphasize the risks with all prescription drugs. The website proposal is understood to be in the internal agency review phase.

You may also be interested in...



“Drug Watch” Website Included In FDA’s Rx Safety Reforms

FDA will launch a Drug Watch website as part of its drug safety reform initiative

“Drug Watch” Website Included In FDA’s Rx Safety Reforms

FDA will launch a Drug Watch website as part of its drug safety reform initiative

U.K. Adverse Events System Will Allow Patients To Submit Reports, Review Data

The Medicines & Healthcare Products Regulatory Agency will have a final system for direct patient reporting of adverse events by 2006, the agency says. MHRA seems to acknowledge the careful balance required to post adverse event data without deterring appropriate drug use.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel